ILC: Interferon-Free Combo Has >95% Virologic Response

Findings among HCV genotype 1 patients previously treated with peginterferon-ribavirin

THURSDAY, April 10, 2014 (HealthDay News) -- An oral, interferon-free drug combination results in a sustained virologic response 12 weeks post-treatment of more than 95 percent in patients with hepatitis C virus (HCV) genotype 1, according to a study published online April 10 in the New England Journal of Medicine. This research was published to coincide with presentation at annual International Liver Congress, held from April 9 to 13 in London.

Stefan Zeuzem, M.D., from the Johann Wolfgang Goethe University in Frankfurt, Germany, and colleagues randomly assigned (3:1) patients with HCV genotype 1 infection (with no cirrhosis who had previously relapsed, had a partial or null response with peginterferon-ribavirin) to receive coformulated ABT-450/ritonavir-ombitasvir (once-daily 150 mg ABT-450, 100 mg ritonavir, 25 mg of ombitasvir) and dasabuvir (250 mg twice daily) with ribavirin (1,000 or 1,200 mg daily) or placebos for a 12-week period. Sustained virologic response 12 weeks after study's end was the primary end point.

The researchers found that 286 of 297 active-regimen patients (96.3 percent) had a sustained virologic response. Compared to the historical control rate, this rate was noninferior and superior. Specifically, virologic response rates were 95.3 percent among those with a prior relapse (82 patients), 100 percent among those with prior partial response (65 patients), and 95.2 percent among those with prior null response (139 patients). Drug-related adverse events requiring discontinuation occurred in three patients.

"Rates of response to a 12-week interferon-free combination regimen were more than 95 percent among previously treated patients with HCV genotype 1 infection, including patients with a prior null response," the authors write.

The trial was funded by AbbVie, the manufacturer of ABT-450/ritonavir, ombitasvir, and dasabuvir.

Full Text
Perspective 1
Perspective 2
More Information

Copyright © 2014 HealthDay. All rights reserved.

Powered by

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles Recommended Nursing Articles

Abdominal Pain: An Approach to a Challenging Diagnosis
AACN Advanced Critical Care, July/September 2014
Free access will expire on October 13, 2014.

HIPAA Compliance Practice Tips
Professional Case Management, July/August 2014
Free access will expire on September 29, 2014.

Follow the leader: How does “followership” influence nurse burnout?
Nursing Management, August 2014
Free access will expire on September 29, 2014.

More Recommended Articles

Subscribe to Recommended Articles

Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events